Copper(II) complexes of methimazole, an anti Grave’s disease drug : Synthesis, characterization and its potential biological behavior as alkaline phosphatase inhibitor

Methimazole (MeimzH<b>)</b> is an anti-thyroid drug and the first choice for patients with Grave’s disease. Two new copper(II) complexes of this drug: [Cu(MeimzH)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>].0.5H<sub>2</sub>O and [Cu(MeimzH)<...

Descripción completa

Detalles Bibliográficos
Autores: Urquiza, Nora M., Manca, Silvia G., Moyano, María Alejandra, Dellmans, Raquel Arrieta, Lezama, Luis, Rojo, Teófilo, Naso, Luciana Gissella, Williams, Patricia Ana María, Ferrer, Evelina Gloria
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2009
País:Argentina
Institución:Universidad Nacional de La Plata
Repositorio:SEDICI (UNLP)
Idioma:inglés
OAI Identifier:oai:sedici.unlp.edu.ar:10915/133155
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/133155
Access Level:acceso abierto
Palabra clave:Química
Methimazole
Copper
Biometals
Grave’s disease
EPR
FTIR
UV-visible
ALP inhibition
Descripción
Sumario:Methimazole (MeimzH<b>)</b> is an anti-thyroid drug and the first choice for patients with Grave’s disease. Two new copper(II) complexes of this drug: [Cu(MeimzH)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>].0.5H<sub>2</sub>O and [Cu(MeimzH)<sub>2</sub>(H<sub>2</sub>O)<sub>2</sub>](NO<sub>3</sub>)<sub>2</sub>·H<sub>2</sub>O were synthesized and characterized by elemental analysis, dissolution behavior, thermogravimetric analysis and UV-vis, diffuse reflectance, FTIR and EPR spectroscopies. As it is known that copper(II) cation can act as an inhibitor of alkaline phosphatase (ALP), the inhibitory effect of methimazole and its copper(II) complexes on ALP activity has also been investigated.

Similares en LA Referencia